Recent Changes in the Incidence and Characteristics of Cutaneous Squamous Cell Carcinomas in Finland from 2006 to 2020: A Retrospective Cohort Study

Marika LOUNAS1,2, Leea YLITALO1,2, Teea SALMI1,2, Juha JERNMAN3, Johanna PALVE2,4, Tiina LUUKKAALA5 and Niina KORHONEN1,2
1Department of Dermatology, Tampere University Hospital, Tampere, 2Faculty of Medicine and Health Technology, Tampere University, Tampere, 3Department of Pathology, Tampere University and Fimlab Laboratories, Tampere, 4Department of Plastic Surgery, Tampere University Hospital, Tampere, and 5Research, Development and Innovation Centre, Tampere University Hospital and Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland

Registers recording only 1 tumour per patient do not enable assessment of the real burden of cutaneous squamous cell carcinoma. To investigate recent changes in the incidence and characteristics of tumours, a retrospective 15-year patient cohort study was performed in Finland. Histopathological diagnoses of cutaneous squamous cell carcinomas diagnosed between 2016 and 2020 were obtained from the pathology database and clinical data from patient medical records and combined with previously collected data for the years 2006–2015. Altogether 1,472 patients with 2,056 tumours were identified. The crude incidence increased from 19/100,000 persons in 2006 to 42 in 2020 ($p<0.001$), increasing most in people aged over 80 years. The percentage of tumours located on the trunk increased from 5.3% during the first 5-year period, 2006–2010, to 9.0% in 2016–2020. Also, the location of tumours was significantly different between men and women, as men had more tumours on the scalp and ears, and women on the lower limbs. A slight change in the tumours from poorly to well differentiated and a decrease in the invasion depth were noted between 2006 and 2020. As the burden of tumours continues to increase, more attention should be paid to their prevention.

Key words: cohort study; cutaneous squamous cell carcinoma; incidence; keratinocyte carcinoma; non-melanoma skin cancer; real-world incidence.

Submitted Mar 3, 2024. Accepted after revision Apr 24, 2024
Published May 30, 2024. DOI: 10.2340/actadv.v104.39891
Acta Derm Venereol 2024; 104: adv39891.

Corr: Marika Lounas, Department of Dermatology, Tampere University Hospital, Tampere/Faculty of Medicine and Health Technology, Tampere University, Teiskontie 35, FIN-33521 Tampere, Finland. E-mail: marika.lounas@tuni.fi

Cutaneous squamous cell carcinoma (cSCC) is the second most common keratinocyte skin cancer (1) and the numbers of these tumours are reported to be increasing worldwide (2, 3). The currently available statistics may be an underestimation, however, as in most epidemiological studies only the patient’s first tumour or only 1 tumour per patient per year will normally have been taken into account (3–5). In reality, a single patient may have multiple cSCC tumours simultaneously or in the course of his or her lifetime (2, 6).

CSCCs cause a significant burden for both society and the affected individual. The costs associated with skin cancers are significant and continue to increase (7). In particular, hospital admissions and medication for advanced skin cancers contribute to the costs, while drug prescriptions account for almost half of the costs in advanced cSCC cases (8). For patients, cSCC and its treatment cause notable inconvenience and also cosmetic problems, because most of the tumours are located in the facial area (3, 9). Functional and psychosocial problems are also common, especially after treatment for metastatic cSCC (10).

We have reported previously that the incidence of cSCC in a patient cohort in Finland increased between 2006 and 2015 (2). Some clarification is needed, however, as to whether the incidence has continued to increase in recent years. Furthermore, there are limited data regarding changes in the incidence figures when each tumour is taken into account separately and also information on changes in tumour characteristics is scarce. The aim of the present work, therefore, was to examine developments in the incidence of cSCCs in the same region of Finland up to the end of the year 2020 and to analyse changes in the clinical and histological characteristics of the tumours.
**MATERIALS AND METHODS**

**Study protocol**

Histopathological diagnoses of “cutaneous squamous cell carcinoma” recorded between 1 January 2016 and 31 December 2020 were searched for in the pathology database of Finlab, which is a provider of laboratory services in the Pirkanmaa region of Finland. The keywords “skin and cutaneous squamous cell carcinoma” and “carcinoma, squamous cell” were used. Only diagnoses of invasive cutaneous squamous cell carcinoma were accepted. In situ cSCC, non-primary cSCC and samples with an uncertain diagnosis were excluded. If the same patient had multiple primary tumours, each of them was taken into account as an independent instance.

The medical records of all the cSCC patients identified in this way were recovered from Tampere University Hospital, the largest hospital in the Pirkanmaa region and its tertiary referral centre. Detailed data on each primary cSCC case were obtained by reviewing both the patient medical records and the histopathological reports. The results of biopsies and excisions were combined for each cSCC tumour individually.

The data on demographic factors included the patient’s age at diagnosis of the primary tumour, sex, and immunosuppression, and the tumour data collected from the patient records or histopathological reports comprised the anatomical localization of the tumour, its degree of differentiation, and the depth of invasion. Tumours were assigned to one of the following 10 anatomical sites: lip, eyelid, ear, face, neck/scalp, trunk, upper extremity, lower extremity, anogenital area, or oral cavity, based on the patient’s medical records. The clinical diameter of the tumour was included if it was reported with sufficient precision in the medical records. In cases where it was suspected that the clinical diameter may have been estimated and not measured, the diameter was excluded from the analysis. In addition, if the patient’s medical records contained a prior history of premalignant skin lesions or other skin cancers in addition to cSCC or current treatment for such before the end of the period defined here, these data were included in the study. The premalignant skin lesions included were actinic keratosis and/or Bowen’s disease and the skin cancers recorded were basal cell carcinoma or cutaneous melanoma. Since the data were collected in exactly the same way as in our previous study (2), we were able to combine the newly collected data with the information obtained from Tampere University Hospital in the same way as in our previous study (2), we were able to combine the newly collected data with the information collected previously to form a 15-year study period extending from 1 January 2006 to 31 December 2020. The only exception was that perineural invasion (PNI), the tumour subtype, and the clinical diameter of the tumour were observed only in the most recent years, 2016–2020.

The institutional review board of Tampere University Hospital, Finland, approved this retrospective study.

**Statistical analysis**

The clinical data and demographic variables for the cSCCs were evaluated using descriptive statistics and frequency tabulation. The data were examined year by year and divided into three 5-year periods. Annual population figures for the Pirkanmaa region were obtained from Statistics Finland for use in the incidence calculations. The population of Pirkanmaa in the last year of the study, 2020, was 522,852. (11) Annual incidence rates were expressed as the number of cSCC cases per 100,000 population. The numerator of the incidence rate was the number of cSCC cases diagnosed in each calendar year, independently of the number of patients. Patients could be counted more than once in a year if they had more than 1 primary tumour during that time.

Categorical data were described by the number of patients with percentages. Differences between the categorical variables were tested using Pearson’s χ² test or Fisher’s exact test. Due to the skewed distributions, continuous variables were shown by medians with interquartile ranges, or else ranges and differences between the two distributions were tested by Mann–Whitney test. Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 software (IBM Corp, Armonk, NY, USA). The statistical significances of trends in annual numbers were tested with the χ² test, those of trends in proportions by RStudio version 1.4.1103 (R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/). Two-sided p-values under 0.05 were considered statistically significant.

**RESULTS**

After excluding 70 cases that did not meet the inclusion criteria and 448 samples due to diagnostic duplication (i.e., biopsies and final excisions of exactly the same cSCC tumours), altogether 698 patients with 925 cSCC tumours diagnosed between 2016 and 2020 were identified, which meant that a total of 1,472 patients with 2,056 cSCC tumours were observed during the entire period 2006–2020 (Table 1). The number of tumours per patient ranged from 1 to 28.

The annual number of cSCC tumours increased from 88 in 2006 to 220 in 2020, and similar increases were observed in the numbers of men and women (51 to 135 in men and 37 to 85 in women, p <0.001 in all the analyses). The crude incidence increased from 19 per 100,000 persons in 2006 to 42 in 2020 (p <0.001) (Fig. 1), and an increasing trend was found in both men (21.9 to 52.4) and women (15.2 to 32.0) during the same period (p <0.001). During the more recent period, 2016–2020, the age-specific incidence increased especially markedly in the groups aged 80 years or over (Fig. 2). The median age of the cSCC patients at the time of the first tumour in the same period was 80 years (interquartile range 73–86) for men and 83 (IQR 75–88) for women. The median age of the women was also 83 between 2006–2015 but only in 2016–2020.

### Table 1. Characteristics of patients with cutaneous squamous cell carcinoma in 2006–2020 (n = 1,472)

<table>
<thead>
<tr>
<th>Factor</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>791 (53.7)</td>
</tr>
<tr>
<td>Women</td>
<td>681 (46.3)</td>
</tr>
<tr>
<td>Age, years, n (%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>60 (4.1)</td>
</tr>
<tr>
<td>60–69</td>
<td>147 (10.0)</td>
</tr>
<tr>
<td>70–79</td>
<td>458 (31.1)</td>
</tr>
<tr>
<td>80–89</td>
<td>607 (41.2)</td>
</tr>
<tr>
<td>&gt; 90</td>
<td>200 (13.6)</td>
</tr>
<tr>
<td>Immunosuppression, n (%)</td>
<td>151 (10.3)</td>
</tr>
<tr>
<td>Heart transplant</td>
<td>10</td>
</tr>
<tr>
<td>Kidney transplant</td>
<td>39</td>
</tr>
<tr>
<td>Liver transplant</td>
<td>6</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>43</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>24</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>24</td>
</tr>
<tr>
<td>Others*</td>
<td>5</td>
</tr>
<tr>
<td>Actinic keratosis and/or Bowen’s disease*, n (%)</td>
<td>1047 (71.1)</td>
</tr>
<tr>
<td>Basal cell carcinoma*, n (%)</td>
<td>558 (37.9)</td>
</tr>
<tr>
<td>Cutaneous melanoma*, n (%)</td>
<td>91 (6.2)</td>
</tr>
</tbody>
</table>

*Treatment with BRAF inhibitor or lung transplant. *Patients were indicated as having actinic keratosis, Bowen’s disease, basal cell carcinoma, or cutaneous melanoma if any prior history or current treatment of such a lesion was recorded in the clinical notes before the end of the period studied here.
was also a significant sex difference in scalp and neck tumours, the men having 79.6% of these and the women 20.4%. In total, 69.9% of the tumours located on the trunk were in men and 30.1% in women (Fig. 3).

Comparing the characteristics of the tumours between 5-year periods, the majority of cSCCs (48.2%) were well differentiated between 2016 and 2020 but the number of poorly differentiated tumours was shown to decrease. Most tumours had an invasion depth of less than 2 mm in each 5-year period and the percentage of tumours with an invasion depth of over 4 mm decreased from 9.7% in the first period to 8.4% in 2016–2020. Perineural invasion and tumour diameters were only investigated in the interval 2016–2020, the outcome being that perineural invasion was present in 29 cases (3.1%), and 48.2% of the tumours were under 2.0 centimetres in diameter, with only 3.2% over 4.0 cm in diameter (Table II).

**DISCUSSION**

The results showed that the numbers and incidences of cSCCs in Finland were still increasing during the most recent period studied, 2016–2020, especially in people aged 80 years or older. Even though cSCCs were shown to have become more common in both sexes, the increased figures were more evident among men. In parallel to our findings, incidence rates have been shown previously to increase with age and be associated with male sex (12). An ageing population is a
challenge faced by many countries, including Finland, so that where 23.3% of Finns were over 65 years old in 2022, it is estimated that by 2060 the percentage will be 30.9% (13). Ageing of the population combined with increasing incidence of cSCCs among older individuals will lead to a substantial increase in the number of cSCCs and subsequently to a growing need for healthcare services to treat skin cancers. Moreover, as the population ages the number of individuals with multiple medication is likely to increase (14), which could also potentially affect the incidence of cSCC. Clinicians should be aware of drugs that are associated with increased rates of skin cancer, such as cyclosporine and azathioprine, and carefully monitor the skin of patients who take these drugs (15).

The exact reasons for the rising trend in the numbers of cSCC cases remain unclear, but several factors are thought to be implicated. It appears that cumulative UV exposure predisposes individuals to the development of cSCCs (16) and most cSCCs arise in the context of actinic keratosis in patients with chronic photoaging. The mechanism of cSCC development is thought to be hyperproliferation of keratinocytes, which requires multiple gene mutations, making transformation into cSCC complicated, so that it often takes many years (12). The use of a sunscreen seems to reduce the risk of cSCC, (17) while β-human papillomavirus and smoking have been shown in previous studies to have the opposite effect. (12) Furthermore, it is known that people with immunosuppression have a greater risk of developing a cSCC, (17) while β-human papillomavirus and smoking have been shown in previous studies to have the opposite effect. (12) Education for patients on photoprotection and also skin examinations are necessary in order to reduce the risk of skin cancers (19). A systematic review of the effects of behavioural counselling for skin cancer prevention showed that interventions can increase sun protection behaviour but, even so, the evidence on whether such interventions are associated with decreased sunburn frequency was not conclusive (20).

### Table II. Characteristics of cutaneous squamous cell tumours in 2006–2020

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumour location</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>36 (7.4)</td>
<td>16 (2.5)</td>
<td>25 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Eyelid</td>
<td>All, n&lt;10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ear</td>
<td>46 (9.5)</td>
<td>60 (9.3)</td>
<td>96 (10.4)</td>
<td></td>
</tr>
<tr>
<td>Face</td>
<td>225 (46.3)</td>
<td>339 (52.6)</td>
<td>427 (46.2)</td>
<td></td>
</tr>
<tr>
<td>Scalp, neck</td>
<td>33 (6.8)</td>
<td>58 (9.0)</td>
<td>108 (11.7)</td>
<td></td>
</tr>
<tr>
<td>Trunk</td>
<td>26 (5.3)</td>
<td>35 (5.4)</td>
<td>83 (9.0)</td>
<td></td>
</tr>
<tr>
<td>Upper limb</td>
<td>64 (13.2)</td>
<td>72 (11.2)</td>
<td>92 (9.9)</td>
<td></td>
</tr>
<tr>
<td>Lower limb</td>
<td>34 (7.0)</td>
<td>34 (5.3)</td>
<td>63 (6.8)</td>
<td></td>
</tr>
<tr>
<td>Anogenital area</td>
<td>15 (3.1)</td>
<td>16 (2.5)</td>
<td>17 (1.8)</td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>All, n&lt;10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumour differentiated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>199 (40.9)</td>
<td>322 (49.9)</td>
<td>446 (48.2)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>216 (44.4)</td>
<td>234 (36.3)</td>
<td>399 (43.1)</td>
<td></td>
</tr>
<tr>
<td>Poorly</td>
<td>38 (7.8)</td>
<td>51 (7.9)</td>
<td>52 (5.6)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>33 (6.6)</td>
<td>38 (5.9)</td>
<td>28 (3.0)</td>
<td></td>
</tr>
<tr>
<td>Tumour invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1mm</td>
<td>18 (3.7)</td>
<td>27 (4.2)</td>
<td>50 (5.4)</td>
<td></td>
</tr>
<tr>
<td>1.0–2.0mm</td>
<td>113 (23.3)</td>
<td>200 (31.0)</td>
<td>322 (34.8)</td>
<td></td>
</tr>
<tr>
<td>2.1–4.0mm</td>
<td>79 (16.3)</td>
<td>124 (19.2)</td>
<td>166 (17.9)</td>
<td></td>
</tr>
<tr>
<td>&gt;4.0mm</td>
<td>47 (9.7)</td>
<td>65 (10.1)</td>
<td>78 (8.4)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>229 (47.1)</td>
<td>229 (35.5)</td>
<td>309 (33.4)</td>
<td></td>
</tr>
<tr>
<td>Perineural invasion</td>
<td>NA</td>
<td>NA</td>
<td>29 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Tumour diameter</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 cm</td>
<td>256 (27.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.0–1.9 cm</td>
<td>190 (20.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.0–3.9 cm</td>
<td>114 (12.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥4.0 cm</td>
<td>30 (3.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>335 (36.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 3. Incidence of cutaneous squamous cell carcinoma tumours in 2006–2020, by location (eyelids, anogenital area, and oral cavity excluded), calculated separately for men and women.
Limited data are available concerning the differences
in the anatomical distribution of cSCC between the
sexes (21), but the present results show that the men
had more tumours on the scalp and ears during a 15-
year follow-up, which is in line with previous findings
(21, 22). One reason for this may be general differences
in hairstyle and clothing that expose certain anatomical
locations in men to more sunlight than in women. On
the other hand, women had slightly more tumours on
the lower legs, as already observed in other studies (21,
23). Different clothing and sunbathing habits compared
with men might at least partly explain this but the role of
repeated depilation of the lower extremities in causing
chronic inflammation has also been speculated (21).
Further studies are needed to investigate the reasons
more carefully. In one Australian cohort the incidence
of cSCC located on the trunk was higher in women than
in men (22), but in our Finnish population the opposite
was the case, as almost three-quarters of the trunk cSCCs
were in men. The incidence of tumours on the trunk in
our cohort increased with time, as has also been seen
previously in a Norwegian study (23). Even though the
majority of tumours were located on the face, there were
also a significant number situated below the neck. It is
therefore of the utmost importance that physicians allow
themselves enough time to examine the whole body.
This is particularly important during follow-up visits,
especially if the patient has already had a premalignant or
malignant lesion (24). The effectiveness of skin screening
by a non-dermatologist needs to be studied more, but it
seems at least that dermatologists find melanomas at an
earlier stage than do general practitioners or the patients
themselves (25). Finding a skin cancer at an early stage
is crucial as it reduces the cost of treatment (26).

It is notable that a slight change was observed here
from poorly to well-differentiated tumours. Almost half
of the tumours were well differentiated, as also reported
previously (27, 28), and the invasion depth was also
slightly shallower in the recent data than in the previous
period. Several tumour-related high-risk factors have
been identified and are listed in European consensus-
based interdisciplinary guidelines (12), so that the grade
of tumour differentiation is one independent prognostic
factor for overall survival and metastatic disease (27).
Also, other features, such as male sex, presence of co-
morbidities, immunosuppression, and actinic keratosis,
have been associated with keratinocyte cancer progres-
sion (29). Furthermore, the clinical size of a tumour is
also one recognized prognostic factor, so that the TNM
classification and several guidelines use clinical size as
the main high-risk feature. It is therefore recommended
to measure the tumour before excision (12). The tumour’s
clinical size was stated accurately enough to be recorded
in only 63.8% of cases in our cohort, leaving room for
improvement. In general, it is important to get enough
information on tumours in order to formulate a prognosis
and decide on the best treatment. As there is no inter-
national consensus on the follow-up schedule for cSCC
patients, schedules need to be planned individually based
on intrinsic and extrinsic risk factors (30).

The strength of our study is that it is one of few to
record each tumour individually, as we used histological
and clinical records and were able to confirm the diag-
nosis reliably, to remove duplicates (if several samples
were taken from one tumour), and to distinguish residual
tumours from primary tumours in order to analyse time
trends and the characteristics of the tumours.

Due to the retrospective nature of the study, it has
some limitations. It was not possible to collect all the
relevant information on each cSCC, and in some cases
the clinical information was not accurate enough to be
included. Moreover, it is possible that we may still have
underestimated the burden of cSCCs, as a few of them
may have been treated completely in the private sector
and were thus not included in our cohort. In view of the
nature of the Finnish healthcare system, however, and
the national guidelines concerning cSCCs, we assume
that the number of tumours treated outside the public
health sector is low.

In conclusion, the incidence of cSCC is still increasing
significantly, especially in older patients, and a slight
rise in the proportion of tumours located on the trunk or
lower limbs highlights the importance of a whole-body
examination in order to find premalignant lesions and
small tumours early enough to avoid extensive excisions.
As the burden of cSCC increases, attention must be paid
to providing adequate resources for the treatment and
prevention of skin cancers.

ACKNOWLEDGEMENTS

Funding sources: This study was supported financially by the
Finnish Dermatological Society, Tampere University Hospital
Support Foundation, Tampere University Hospital/ Project No.
MK364, Competitive State Research Financing for the Expert
Responsibility area of Tampere University Hospital /Project No.
9AC053 and the Finnish Cultural Foundation (grants awarded to
Dr Lounas). These organizations were not involved in any way in
the study design, the collection, analysis or interpretation of the
data, the writing of the manuscript, or the decision to submit the
manuscript for publication.

IRB approval status: The institutional review board of Tampere
University Hospital, Finland, approved this retrospective study.

The authors have no conflicts of interest to declare.

REFERENCES

1. Que S, Zwalf F, Schmults C. Cutaneous squamous cell carci-
noma: incidence, risk factors, diagnosis, and staging. J Am
2. Korhonen N, Ylitalo L, Luukkaala T, Itkonen J, Hähälä H,
Jernman J, et al. Characteristics and trends of cutaneous
squamous cell carcinoma in a patient cohort in Finland